IGF-1 LR3 (1 mg)

83-AA Recombinant IGF-1 Analog: Long R3 modifications confer ~3× potency vs. native IGF-1 and 20-30h half-life, ≥98% purity
Reduced IGFBP Binding / Dual Signaling: Bypasses IGFBP sequestration; activates IGF-1R via PI3K/Akt/mTOR and MAPK/ERK cascades
Cell Culture & Preclinical Research: Replaces insulin at 200-fold lower concentrations; validated in 22+ peer-reviewed publications

Manufacturer: RiboCore

Availability: 100 in stock

SKU: RP-IGF-1MG

$64.00

Ship to

Shipping Method

Estimated Delivery

Price

No shipping options

Technical Specifications

Characteristic	Value
CAS Number	946870-92-4
Molecular Weight	9,117.50 Da (~9.1 kDa)
Molecular Formula	C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
Purity	≥98% by HPLC
Form	Lyophilized powder, 1 mg per vial
Sequence Length	83 amino acids

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic 83-amino acid recombinant analog of human IGF-1, engineered in the early 1990s by scientists at GroPep Limited (Adelaide, Australia) through collaborations with CSIRO and the University of Adelaide. Two critical modifications distinguish it from native 70-AA IGF-1: (1) a glutamic acid to arginine substitution at position 3 ("R3"), and (2) a 13-amino acid N-terminal extension (MFPAMPLSSLFVN). These modifications confer markedly reduced affinity for the six high-affinity IGF-binding proteins (IGFBPs), approximately three-fold greater potency at the IGF-1 receptor (IGF-1R), and a significantly extended half-life of approximately 20-30 hours. Intended strictly for qualified researchers, IGF-1 LR3 is supplied as a lyophilized powder for in vitro research and has been validated in over 22 peer-reviewed publications.

IGF-1 LR3 was originally developed as a cell culture supplement to replace insulin at dramatically lower concentrations (200-fold). Its reduced IGFBP binding makes it a pharmacological tool for studying IGF-1R-mediated signaling without IGFBP sequestration confounds. The compound has never been approved for human therapeutic use and is classified under Section S2 of the World Anti-Doping Agency (WADA) Prohibited List as a peptide hormone.

Key Research Highlights

Research Area	Key Finding
Cardiomyocyte Proliferation	LR3 stimulated fetal sheep cardiomyocyte BrdU uptake 3-5 fold (hyperplastic response); both ERK and PI3K pathways required (Sundgren et al., 2003)
Atherosclerotic Plaque Stabilization	ApoE-KO mouse infusion: reduced stenosis, doubled cap/core ratio, increased vSMC content 2-fold, reduced intraplaque hemorrhage from 16% to 4% (von der Thusen et al., 2011)
Fetal Organ Growth	1-week IV infusion in fetal sheep: heart +34%, adrenals +31%, spleen growth observed without proportional carcass mass increase (Stremming et al., 2021)
GI Trophic Effects	6.5-day rat infusion: gut weight +60%, gut length +32%, kidney weight +85%; more potent than native IGF-1 for all parameters (Steeb et al., 1997)

Research Applications

Serum-Free Cell Culture Bioprocessing (CHO, HEK293, hybridoma systems)
IGF-1R Signaling Research (PI3K/Akt/mTOR and MAPK/ERK pathway studies)
Cardiovascular Biology and Vascular Smooth Muscle Cell Studies
Fetal Development and Developmental Physiology Research
Gastrointestinal Epithelial Proliferation Research
Neuroscience and Amyloid Plaque Biology Models
GH-IGF-1 Axis Feedback and Metabolic Signaling Studies
Anti-Doping Analytical and Pharmacokinetic Research

Research Use Only. This product is supplied for in vitro laboratory investigation by qualified researchers. Not for human or veterinary consumption, diagnosis, treatment, prevention, or cure of any condition. Not approved by the FDA for human use.